Literature DB >> 18850578

Transition zone and anterior stromal prostate cancers: zone of origin and intraprostatic patterns of spread at histopathology.

Sébastien Bouyé1, Eric Potiron, Philippe Puech, Xavier Leroy, Laurent Lemaitre, Arnauld Villers.   

Abstract

BACKGROUND: To describe the precise location of transition zone (TZ) and anterior fibromuscular stroma (AFMS) prostate cancers (TZ/AFMS) within histological zones at various stages of development and to demonstrate their pattern of intraprostatic spread from their site of origin.
METHODS: Anterior TZ/AFMS cancers excluding the anterolateral part of peripheral zone, were identified from radical prostatectomy specimens. Morphometric histopathological study included largest surface area, volume and spatial distribution.
RESULTS: Out of 91 TZ/AFMS cancers, 79 were <4 cm3 and 69 <2 cm3. Fifty percent and 70% of cancers <4 cm3 were located in the anterior third and inferior half of TZ and/or AFMS, respectively. Cancers <2 cm3 could be classified into three types according to their location related to histologic zone boundaries: TZ type 1 (40%) for cancers confined to one TZ lobe; TZ type 2 (35%) for cancers most represented in one TZ lobe but crossing its anterior boundary; type AFMS (25%) for cancers confined to AFMS. These results form the rationale for the hypothesis that AFMS cancers originate from anterior and medial TZ and due to benign prostatic hypertrophy they become excluded from TZ, anteriorly into AFMS. TZ anterior limit would then act as a barrier to their posterior extension.
CONCLUSIONS: TZ/AFMS cancers contours and locations are predictable and conform to histological zones boundaries. Knowledge of these cancer origin and pattern of spread in TZ and AFMS are of importance for imaging diagnosis, guidance for biopsy and focal therapy. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 18850578     DOI: 10.1002/pros.20859

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  24 in total

1.  Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer.

Authors:  Hashim U Ahmed; Oguz Akin; Jonathan A Coleman; Sarah Crane; Mark Emberton; Larry Goldenberg; Hedvig Hricak; Mike W Kattan; John Kurhanewicz; Caroline M Moore; Chris Parker; Thomas J Polascik; Peter Scardino; Nicholas van As; Arnauld Villers
Journal:  BJU Int       Date:  2011-11-11       Impact factor: 5.588

2.  The diagnostic value of PI-RADS V1 and V2 using multiparametric MRI in transition zone prostate clinical cancer.

Authors:  Ximing Wang; Jie Bao; Xiaoxia Ping; Chunhong Hu; Jianquan Hou; Fenglin Dong; Lingchuan Guo
Journal:  Oncol Lett       Date:  2018-06-28       Impact factor: 2.967

3.  Variable correlation of grid coordinates to core location in template prostate biopsy.

Authors:  Christopher M Brede; Nicholas J Douville; Stephen Jones
Journal:  Curr Urol       Date:  2013-02-08

Review 4.  Management of rising prostate-specific antigen after a negative biopsy.

Authors:  David A Levy; J Stephen Jones
Journal:  Curr Urol Rep       Date:  2011-06       Impact factor: 3.092

Review 5.  MRI of localized prostate cancer: coming of age in the PSA era.

Authors:  Barış Türkbey; Marcelino Bernardo; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke
Journal:  Diagn Interv Radiol       Date:  2011-09-16       Impact factor: 2.630

6.  The Clinical Value of Performing an MRI before Prostate Biopsy.

Authors:  Myung Sun Choi; Yong Sun Choi; Byung Il Yoon; Su Jin Kim; Hyuk Jin Cho; Sung Hoo Hong; Ji Youl Lee; Tae-Kon Hwang; Sae Woong Kim
Journal:  Korean J Urol       Date:  2011-08-22

7.  Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidance.

Authors:  J P Radtke; S Boxler; T H Kuru; M B Wolf; C D Alt; I V Popeneciu; S Steinemann; C Huettenbrink; C Bergstraesser-Gasch; T Klein; C Kesch; M Roethke; N Becker; W Roth; H-P Schlemmer; M Hohenfellner; B A Hadaschik
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-06-16       Impact factor: 5.554

8.  Outcome of repeated prostatic biopsy during active surveillance: implications for focal therapy.

Authors:  Ghassan A Barayan; Armen G Aprikian; James Hanley; Wassim Kassouf; Fadi Brimo; Louis R Bégin; Simon Tanguay
Journal:  World J Urol       Date:  2014-11-12       Impact factor: 4.226

9.  Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails.

Authors:  Amy S Duffield; Thomas K Lee; Hiroshi Miyamoto; H Ballantine Carter; Jonathan I Epstein
Journal:  J Urol       Date:  2009-09-16       Impact factor: 7.450

10.  Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology.

Authors:  Martin J Magers; Tianyu Zhan; Aaron M Udager; John T Wei; Scott A Tomlins; Angela J Wu; Lakshmi P Kunju; Madelyn Lew; Felix Y Feng; Daniel A Hamstra; Javed Siddiqui; Arul M Chinnaiyan; Jeffrey S Montgomery; Alon Z Weizer; Todd M Morgan; Brent K Hollenbeck; David C Miller; Ganesh S Palapattu; Hui Jiang; Rohit Mehra
Journal:  Med Oncol       Date:  2015-10-06       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.